03-05-2018 – ETBI – EastGate Biotech Announces Licensing/Distribution MOU With BuPharco for the Insulin Mouth Rinse in the Philippines for Type 2 Diabetes Patients
WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 5, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes. We are thrilled to announce today that EastGate has signed a Memorandum of Understanding (MOU) with Bukidnon Pharmaceutical Multi-Purpose Cooperatives (BuPharco). The MOU outlines the strategic plan to commercialize the oral insulin mouth rinse delivered through the buccal mucosa (inner lining of mouth) and penetrates the blood brain barrier. BuPharco will initially compile, submit, and file all dossiers to the FDA...
